Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 7/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394806 | 0.82 | IRAK4 (0.46) | IRAK4FFAR1LPLLIPGESR2 | |
| SCHEMBL31387118 | 0.81 | IRAK4 (0.43) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL22551943 | 0.78 | IRAK4 (0.41) | IRAK4FFAR1LPLLIPGESR2 | |
| SCHEMBL26352649 | 0.76 | IRAK4 (0.40) | IRAK4FFAR1 | |
| SCHEMBL29425316 | 0.76 | IRAK4 (0.40) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL25335146 | 0.75 | TGFBR1 (0.44) | IRAK4 | |
| SCHEMBL22650904 | 0.75 | IRAK4 (0.39) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL30483016 | 0.73 | LPL (0.49) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL25802396 | 0.71 | EPHB3 (0.40) | — | |
| SCHEMBL26596835 | 0.71 | FYN (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146647-B1 | CDK INHIBITORS | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250325544-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250281487-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250275972-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250275971-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-12285429-B2 | CDK inhibitors | GENENTECH, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250064806-A1 | CDK INHIBITORS | GENENTECH, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240033264-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| EP-4146647-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2023-03-15 | — | — | EP | disclosed |
| CN-115803327-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2021226140-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2021-11-11 | — | — | WO | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281487-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | IRAK4 2461/4885FFAR1 4667/4885LPL 4864/4885 |
| US-20240033264-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | IRAK4 2331/4885FFAR1 4677/4885LPL 4837/4885 |
| US-20240066031-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | IRAK4 2331/4885FFAR1 4677/4885LPL 4837/4885 |
| US-20250064806-A1 | CDK INHIBITORS | CDK9, CDK6, CDK3 | IRAK4 2382/4885FFAR1 4664/4885LPL 4829/4885 |
| US-12285429-B2 | CDK inhibitors | CDK9, CDK3, CDKL1 | IRAK4 2613/4885FFAR1 4730/4885LPL 4817/4885 |
| US-20250325544-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | IRAK4 2461/4885FFAR1 4667/4885LPL 4864/4885 |
| US-20250275972-A1 | CDK INHIBITORS | CDK9, CDK6, CDK3 | IRAK4 2382/4885FFAR1 4664/4885LPL 4829/4885 |
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | IRAK4 2748/4885FFAR1 4637/4885LPL 4724/4885 |
| US-20230174512-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | IRAK4 2331/4885FFAR1 4677/4885LPL 4837/4885 |
| US-20250275971-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | IRAK4 2461/4885FFAR1 4667/4885LPL 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.